In cancer, mutations in APC or CTNNB1 (β-catenin) lead to permissive β-catenin machinery, subverting TCF/LEF transcription factors to unleash tumorigenic gene expression, including MYC, CCND1, and AXIN2, promoting unbridled proliferation, stemness, and therapeutic resistance. This evidence concerns the gene MYC and cancer.